CUS0 Stock Overview
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Curis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.68 |
| 52 Week High | US$15.50 |
| 52 Week Low | US$3.68 |
| Beta | 3.32 |
| 11 Month Change | -17.86% |
| 3 Month Change | -15.98% |
| 1 Year Change | n/a |
| 33 Year Change | -96.55% |
| 5 Year Change | -86.37% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUS0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -20.0% | -0.4% | -1.8% |
| 1Y | n/a | -15.4% | 13.6% |
Return vs Industry: Insufficient data to determine how CUS0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how CUS0 performed against the German Market.
Price Volatility
| CUS0 volatility | |
|---|---|
| CUS0 Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CUS0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CUS0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 49 | Jim Dentzer | www.curis.com |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
Curis, Inc. Fundamentals Summary
| CUS0 fundamental statistics | |
|---|---|
| Market cap | €32.19m |
| Earnings (TTM) | -€43.74m |
| Revenue (TTM) | €9.34m |
3.6x
P/S Ratio-0.8x
P/E RatioIs CUS0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUS0 income statement (TTM) | |
|---|---|
| Revenue | US$10.16m |
| Cost of Revenue | US$40.39m |
| Gross Profit | -US$30.23m |
| Other Expenses | US$17.35m |
| Earnings | -US$47.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.68 |
| Gross Margin | -297.48% |
| Net Profit Margin | -468.18% |
| Debt/Equity Ratio | -5,527.2% |
How did CUS0 perform over the long term?
See historical performance and comparison